17-Allylaminogeldanamycin

CAS: 75747-14-7

Ref. 3D-AA17307

Información del producto

• Nombre: 17-Allylaminogeldanamycin
• Sinónimos: 17-Demethoxy-17-(2-propenylamino)geldanamycinTelatinibTanespimycin17-AAG, (4Z,6E,10E)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-(prop-2-en-1-ylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate, (8R,9R,12R,13S,14R,16R)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-(prop-2-en-1-ylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate, (8S,9S,12S,13R,14S,16R)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-(prop-2-en-1-ylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate, 17-(Allylamino)-17-demethoxygeldanamycin, 17-(Allylamino)-17-desmethylgeldanamycin, 17-(Allylamino)geldanamycin, 17-Allylaminodemethoxygeldanamycin, 17-Demethoxy-17-(2-propenylamino)geldanamycin, 17-Demethoxy-17-allylaminogeldanamycin, 17-N-Allylamino-17-demethoxygeldanamycin, 17Aag, 2-Azabicyclo[16.3.1]docosane, geldanamycin deriv., A 8476, Bms 722782, Cp 127374, Geldanamycin, 17-demethoxy-17-(2-propenylamino)-, Kos 953, NSC 330507, Tanespimycin

Descripción

17-AAG is the first clinically tested hsp90 inhibitor that exhibits antitumor activity. Its antitumor effects are documented in vivo for various animal models, including erbB2-dependent breast cancer, prostate cancer models, and melanoma.

• Marca: Biosynth

Propiedades químicas

• Peso molecular: 585.69 g/mol
• Fórmula: C₃₁H₄₃N₃O₈
• Pureza: Min. 95%
• Color/Forma: Powder